Cytosorbents Corporation (NASDAQ:CTSO)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Tuesday. They currently have a $13.00 target price on the medical research company’s stock. HC Wainwright’s price objective would indicate a potential upside of 100.00% from the stock’s previous close.

Several other research firms have also recently issued reports on CTSO. B. Riley reiterated a “buy” rating and set a $11.25 target price on shares of Cytosorbents Corporation in a research report on Friday, November 10th. Maxim Group reiterated a “buy” rating and set a $12.00 target price on shares of Cytosorbents Corporation in a research report on Friday, November 10th. ValuEngine cut Cytosorbents Corporation from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. Finally, Aegis reiterated a “buy” rating and set a $9.00 target price on shares of Cytosorbents Corporation in a research report on Tuesday, July 25th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $10.45.

Cytosorbents Corporation (NASDAQ CTSO) traded up $0.25 during trading hours on Tuesday, hitting $6.50. The company had a trading volume of 196,600 shares, compared to its average volume of 131,089. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.36 and a quick ratio of 3.17. Cytosorbents Corporation has a 12-month low of $3.30 and a 12-month high of $6.70.

ILLEGAL ACTIVITY NOTICE: “HC Wainwright Reaffirms “Buy” Rating for Cytosorbents Corporation (CTSO)” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/11/21/hc-wainwright-reaffirms-buy-rating-for-cytosorbents-corporation-ctso.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Fortaleza Asset Management Inc. grew its holdings in Cytosorbents Corporation by 81.6% during the 3rd quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock valued at $145,000 after buying an additional 10,500 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in Cytosorbents Corporation by 145.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock valued at $163,000 after buying an additional 22,500 shares in the last quarter. Finally, Wealthcare Advisory Partners LLC purchased a new position in Cytosorbents Corporation during the 3rd quarter valued at approximately $365,000. Institutional investors and hedge funds own 6.27% of the company’s stock.

Cytosorbents Corporation Company Profile

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Analyst Recommendations for Cytosorbents Corporation (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.